<span item_type="fundamental" item_id="700fcfcf645f192a29842053a0814a22" counter_id="ST/US/DMAAR" env="prod"></span><span item_type="announcement" item_id="518297578643984385" env="prod"></span><p>每股收益：截至 2025 财年 Q1，公布值为 0.05 美元。</p><p></p><h3>财务指标</h3><h4>净收入</h4><ul><li>截至 2025 年 3 月 31 日的三个月净收入为 1,254,543 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h4>运营成本</h4><ul><li>一般和行政成本为 330,925 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h4>现金流</h4><ul><li>运营活动现金流为-251,244 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>投资活动现金流为-231,150,000 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>融资活动现金流为 231,400,816 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h4>资产负债</h4><ul><li>截至 2025 年 3 月 31 日，总资产为 232,806,487 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>总负债为 7,247,369 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h4>独特指标</h4><ul><li>信托账户中的现金和投资为 232,735,468 美元。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h3>未来展望和战略</h3><ul><li>公司计划在 15 个月内完成首次业务合并，若未能完成，时间可延长至最多 21 个月。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>公司将继续在制药行业寻找业务合并目标。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>公司计划使用信托账户中的资金进行业务合并，并可能使用股权或债务作为合并的对价。<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul>

DRUGS MADE IN AMER ACQUISITION CORP COM USD0.0001 15/10/2029 (SUB/RIGHTS)｜10-Q：2025 财年 Q1 每股收益 0.05 美元